Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT01144793
A Pilot/Observational Study Using a Biomarker Monitoring System to Evaluate Protein Profiles of Neutropenic Fever/Infection in Patients With Acute or Chronic Leukemias Undergoing Chemotherapy or Other Biologic Treatment
Professor of Medicine (Hematology)
Inclusion Criteria:- Age >= 18
- Pre-admission (ATU, ITA) or inpatient status
- absolute neutrophil count (ANC) <= 1500/mm^3
- Patients with acute myeloid or lymphoid leukemia who:
- are admitted with newly diagnosed disease and have not yet received induction
chemotherapy
- are admitted with neutropenic fever after receiving post-remission chemotherapy
or are admitted for post-remission chemotherapy
- Patients with chronic myeloid leukemia or a chronic lymphoid leukemia/disorder who
have received chemotherapy or other disease-specific treatment in the last 30 days
where the ANC of <=1500/mm3 is considered by the treating physician to be at least
possibly treatment-related
- An intravenous line or catheter (Hickman, port, portacath, or peripherally inserted
central venous catheter [PICC] line) must be in place at the time of protocol
participation/study start, but will not be inserted solely for the purposes of the
study.
- Whenever possible, patients will be consented and blood monitoring will be initiated
before the first dose of antibiotic, but if not possible, at no time will standard of
care measures will be delayed or interrupted for the purposes of study enrollment.
- Patients must be able to understand the nature of the study and give written informed
consent.
There are no exclusion criteria. Anyone who does not meet inclusion criteria will be
excluded.
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Andrea Linder
6507254047